Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate CancerCompleted
NCT02788773Phase 2Updated May 15, 2025
Sponsor: Canadian Cancer Trials Group
Prostate Cancer
Canada
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.Completed
NCT03528681Phase 3Updated May 14, 2025
Sponsor: AstraZeneca
Hyperkalemia
China, India
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular CarcinomaRecruiting
NCT06911255Phase 1, Phase 2Updated May 14, 2025
Sponsor: Yoon Jun Kim
Hepatocellular Carcinoma (HCC) · Unresectable Hepatocellular Carcinoma
South Korea
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.Completed
NCT06046534N/AUpdated May 13, 2025
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
France, Greece, Israel, Italy, Portugal +2 more
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in BrazilTerminated
NCT06231693N/AUpdated May 8, 2025
Sponsor: AstraZeneca
Breast Cancer
Brazil
Olaparib in Patients With HRD Malignant MesotheliomaRecruiting
NCT04515836Phase 2Updated May 6, 2025
Sponsor: University of Chicago
Mesothelioma · Homologous Recombination Deficiency
United States
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive Not Recruiting
NCT02983578Phase 2Updated May 6, 2025
Sponsor: M.D. Anderson Cancer Center
Advanced Colorectal Carcinoma · Advanced Lung Non-Small Cell Carcinoma · Lung Non-Small Cell Carcinoma · Mismatch Repair Deficiency
United States
Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in BelgiumCompleted
NCT04221802N/AUpdated May 6, 2025
Sponsor: AstraZeneca
Severe Asthma
Belgium
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung CancerCompleted
NCT00328562Phase 1Updated May 4, 2025
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-Small Cell Lung Carcinoma (NSCLC)
United States
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's MetaplasiaCompleted
NCT00357682Phase 3Updated May 1, 2025
Sponsor: University of Oxford
Esophageal Cancer · Precancerous Condition
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated AlbuminuriaCompleted
NCT05570305Phase 2Updated Apr 30, 2025
Sponsor: University Medical Center Groningen
Chronic Kidney Diseases
United States, Canada, Denmark, Netherlands, United Kingdom
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy ParticipantsCompleted
NCT06846528Phase 1Updated Apr 29, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromETerminated
NCT04601467Phase 2Updated Apr 27, 2025
Sponsor: National University Heart Centre, Singapore
Acute Coronary Syndrome
New Zealand, Singapore
Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES DatabasesCompleted
NCT06077045N/AUpdated Apr 27, 2025
Sponsor: AstraZeneca
Influenza
United Kingdom
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug InteractionsCompleted
NCT06671405Phase 1Updated Apr 27, 2025
Sponsor: AstraZeneca
Dyslipidaemia
United States
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.Completed
NCT05787002Phase 1Updated Apr 27, 2025
Sponsor: AstraZeneca
Dyslipidemia
United States
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy ParticipantsCompleted
NCT06194032Phase 1Updated Apr 25, 2025
Sponsor: AstraZeneca
Healthy Participants
Germany
Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety StudyCompleted
NCT04991805N/AUpdated Apr 25, 2025
Sponsor: AstraZeneca
Asthma · Neoplasms
Sweden, United Kingdom
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving DurvalumabActive Not Recruiting
NCT03653052Phase 2Updated Apr 24, 2025
Sponsor: Simon C Pacey, MD
Oesophageal Cancer
United Kingdom
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related TumorsTerminated
NCT03095248Phase 2Updated Apr 22, 2025
Sponsor: Children's Hospital Medical Center, Cincinnati
Neurofibromatosis 2 · Vestibular Schwannoma · Meningioma · Ependymoma
United States
A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)Completed
NCT05924880Phase 3Updated Apr 22, 2025
Sponsor: AstraZeneca
Biliary Tract Cancers
China
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy ParticipantsCompleted
NCT06554821Phase 1Updated Apr 18, 2025
Sponsor: AstraZeneca
Healthy Participants
Germany
AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in PediatricsCompleted
NCT05281601Phase 1Updated Apr 18, 2025
Sponsor: AstraZeneca
SARS-CoV-2
United States, Belgium, Brazil, Germany, United Kingdom
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerActive Not Recruiting
NCT03594396Phase 1, Phase 2Updated Apr 17, 2025
Sponsor: Seoul National University Hospital
Breast Neoplasms
South Korea
A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung CancerTerminated
NCT04870112Phase 1Updated Apr 17, 2025
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer · Small Cell Lung Cancer
United States, New Zealand, Spain, Taiwan

Previous page Next page